ArticleCancer discovery2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with
Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02338622 (A Phase I Multi-centre Trial of the Combination of Olaparib), which is not on this map. Cited by 88 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients With Advanced Solid Tumours
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- Olaparib-associated toxicity in cancer patients: a systematic review and meta-analysis.European journal of clinical pharmacology · 2025Pooled it
- BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).Cancer research communications · 2025Trial
- Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions.The Journal of clinical investigation · 2026Review
- Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance.Journal of clinical medicine · 2026Review
- Article
- High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.International journal of molecular sciences · 2026Review
- Fanconi anemia complementation group C gene (FANCC) association with hereditary and sporadic renal tumors.The oncologist · 2026Article
- Article
- Simultaneous inhibition of PARP/AKT to intercept nascent BRCA1/2NPJ breast cancer · 2026Article
- Targeting the PI3K/AKT/mTOR signaling pathway in prostate cancer: Molecular dysregulation, therapeutic advances, and future directions.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- MicroRNA-based strategies to overcome the immunotherapy barrier in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2026Review
- Enhancing PARP inhibitor efficacy in ovarian cancer: targeting the PI3K/AKT/mTOR pathway.Journal of ovarian research · 2025Review
- Olaparib synergy screen reveals Exemestane induces replication stress in triple-negative breast cancer.Molecular oncology · 2025Article
- Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment.bioRxiv : the preprint server for biology · 2025Article
- Article
- Clinical approaches to overcome PARP inhibitor resistance.Molecular cancer · 2025Review
- Promising new drugs and therapeutic approaches for treatment of ovarian cancer-targeting the hallmarks of cancer.BMC medicine · 2025Review
- Integrating Bibliometrics and Bioinformatics to Map Knowledge Structure, Trends, and Genetic Insights in Polycystic Ovary Syndrome and Tumors (2015-2024).Journal of multidisciplinary healthcare · 2025Article
- AKT inhibitors in gynecologic oncology: past, present and future.Frontiers in oncology · 2025Review
- Capivasertib: First Approved AKT inhibitor for the Treatment of Patients with Breast Cancer.Anti-cancer agents in medicinal chemistry · 2025Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 7 institutions in 4 countries.
Timothy A YapRoyal Marsden Hospital, London, United Kingdom. tyap@mdanderson.org.ORCID https://orcid.org/0000-0002-2154-3309
Rebecca KristeleitUniversity College London, London, United Kingdom.ORCID https://orcid.org/0000-0003-3825-1326
Vasiliki MichalareaRoyal Marsden Hospital, London, United Kingdom.
Stephen J PettittThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0003-3313-3857
Joline S J LimRoyal Marsden Hospital, London, United Kingdom.
Suzanne CarreiraThe Institute of Cancer Research, London, United Kingdom.
Desamparados RodaRoyal Marsden Hospital, London, United Kingdom.
Rowan MillerUniversity College London, London, United Kingdom.
Ruth RiisnaesThe Institute of Cancer Research, London, United Kingdom.
Susana MirandaThe Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0002-5936-2706
Ines FigueiredoThe Institute of Cancer Research, London, United Kingdom.
Daniel Nava RodriguesThe Institute of Cancer Research, London, United Kingdom.
Sarah WardRoyal Marsden Hospital, London, United Kingdom.
Ruth MatthewsRoyal Marsden Hospital, London, United Kingdom.ORCID https://orcid.org/0000-0003-1697-3109
Mona ParmarRoyal Marsden Hospital, London, United Kingdom.
Alison TurnerRoyal Marsden Hospital, London, United Kingdom.
Nina TunariuRoyal Marsden Hospital, London, United Kingdom.ORCID https://orcid.org/0000-0001-6656-3699
Neha ChopraRoyal Marsden Hospital, London, United Kingdom.
Heidrun GevenslebenThe Institute of Cancer Research, London, United Kingdom.
Nicholas C TurnerRoyal Marsden Hospital, London, United Kingdom.
Ruth RuddleThe Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0003-0025-8872
Florence I RaynaudThe Institute of Cancer Research, London, United Kingdom.
Shaun DecordovaThe Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0002-0091-0587
Karen E SwalesThe Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0002-6572-1293
Laura FinneranThe Institute of Cancer Research, London, United Kingdom.
Emma HallThe Institute of Cancer Research, London, United Kingdom.ORCID https://orcid.org/0000-0001-5999-5020
Paul RugmanOncology R&D, AstraZeneca, Cambridge, United Kingdom.
Justin P O LindemannOncology R&D, AstraZeneca, Cambridge, United Kingdom.ORCID https://orcid.org/0000-0003-1531-9754
Andrew FoxleyOncology R&D, AstraZeneca, Cambridge, United Kingdom.
Christopher J LordThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
Udai BanerjiRoyal Marsden Hospital, London, United Kingdom.ORCID https://orcid.org/0000-0003-1503-3123
Ruth PlummerClinical and Translational Research Institute, Newcastle University, Newcastle, United Kingdom.
Bristi BasuDepartment of Oncology, University of Cambridge, Cambridge, United Kingdom.ORCID https://orcid.org/0000-0002-3562-2868
Juanita S LopezRoyal Marsden Hospital, London, United Kingdom.
Yvette DrewClinical and Translational Research Institute, Newcastle University, Newcastle, United Kingdom.ORCID https://orcid.org/0000-0001-6676-9224
Johann S de BonoRoyal Marsden Hospital, London, United Kingdom.
Institute of Cancer Research · GBBreast Cancer Now · GBAstraZeneca (United Kingdom) · GBRoyal Marsden Hospital · GBNewcastle University · GBUniversity College London · GBUniversity of Cambridge · GB
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8MCancer Research UK 11566Cancer Research UK 14276Cancer Research UK 22897Cancer Research UK 24439Department of Health RP-2016-07-028NCI NIH HHS P30 CA016672
Abstract
Preclinical studies have demonstrated synergy between PARP and PI3K/AKT pathway inhibitors in
Indexed as
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinBRCA2 ProteinFemaleHumansMiddle AgedPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPyrimidinesPyrrolesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humancapivasertibolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPyrimidinesPyrroles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02338622ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.